Skip to content


  • Case report
  • Open Access

Concurrent insulinoma and pancreatic adenocarcinoma: report of a rare case and review of the literature

  • 1Email author,
  • 1,
  • 1,
  • 2,
  • 3 and
  • 1
World Journal of Surgical Oncology20119:7

  • Received: 9 November 2010
  • Accepted: 25 January 2011
  • Published:


Pancreatic adenocarcinoma is the 5th leading cause of cancer-related death in Western countries and insulinomas are rare endocrine neoplasms of the pancreas. The concurrent appearance of pancreatic adenocarcinoma and insulinoma is very rare and to the best of our knowledge has never been reported again. Herein, we present such an occurrence in a 74-year-old man. Resection of a mass in the uncinate process of the pancreas revealed pancreatic adenocarcinoma with severe desmoplastic reaction. Two years later, due to symptomatology persistence the patient was re-examined and a new 2cm mass in the uncinate process was found leading to surgery, which demonstrated a 2cm endocrine islet-cell tumor. Establishing a diagnosis in patients with insulinoma is difficult and the imaging studies still have low sensitivity and specificity except for intra-operative ultrasonography, which is the most accurate method detecting 90% of these lesions.


  • Octreotide
  • Pancreatic Adenocarcinoma
  • Insulinoma
  • Endocrine Neoplasm
  • Uncinate Process


Pancreatic endocrine neoplasms are rare tumours with a reported incidence of four cases per million patients per year [1]. Of these tumours, insulinomas are the most common and typically are sporadic and solitary masses affecting individuals 30-60 years old, with equal distribution among genders [2]. On the other hand, pancreatic adenocarcinoma is the 5th leading cause of cancer death in Western countries, and the second cause of cancer death among gastrointestinal tumors [3]. An unusual occurrence of concomitant pancreatic adenocarcinoma and insulinoma in a 74-year-old man is presented herein.

Case Presentation

A 74-year-old man was admitted to our hospital, suffering for the last 2 years from hypoglycaemic attacks. Laboratory tests showed fasting glucose level below 50mg/dl and symptoms of hypoglycaemia such as tachycardia, sweating, confusion and light-headedness. The correction of the above when glucose was administered was significant, so the Whipple's triad was present. Plasma-insulin level, measured through the extended 72-hours fasting test was found 12mIU/ml and C-peptide level was also elevated, 4.3ng/ml. Tumour markers were within normal range apart from Ca 19-9 which was 5IU/ml.

Abdominal ultrasonography (US) did not reveal any lesion, but a contrast enhanced CT scan demonstrated a 1.5cm solid mass in the uncinate process of the pancreas (Figure 1). The patient underwent surgical exploration and pancreas palpation indeed revealed a small solid mass in the uncinate process, which was resected with a small amount of normal tissue surrounding the mass. No frozen section biopsy was done since we believed that the mass represented the insulinoma. However, the histopathological study featured a pancreatic adenocarcinoma of about 1mm in maximum diameter with intense desmoplastic reaction around the lesion (Figure 2). We estimated that the performed resection was enough treatment for such a small carcinoma. The patient's postoperative course was uneventful and he was discharged on the seventh postoperative day with a regular follow-up as the only recommendation.
Figure 1
Figure 1

Contrast enhanced CT scan depicting the 1.5 cm solid mass in the uncinate process of the pancreas (arrow).

Figure 2
Figure 2

Microscopic focus of pancreatic adenocarcinoma with desmoplastic reaction (Hematoxylin-Eosin × 400).

Serial evaluation of Ca 19-9, at 3-month intervals, during the following two years, was found within normal range. Due to persistence of hypoglycaemic symptoms, successive abdominal CT scans completed the follow-up [4] but they were inconclusive because of the increased postoperative inflammatory reaction in the region of the resection. Thus, hypoglycaemic symptoms were classified as idiopathic and were significantly improved with appropriate dietary modifications. After two years, better CT image resolution presumably due to regression of the inflammatory phenomena, rendered the insulinoma mass detectable again, having at that time increased its size from 1.5cm to 2cm (Figure 3). Another operation was decided and pancreaticoduodenectomy was performed. The histopathological examination revealed a 2cm endocrine islet-cell tumour (Figure 4, 5) and the patient was discharged on the tenth postoperative day.
Figure 3
Figure 3

Contrast enhanced CT scan, after the first operation, demonstrating a 2 cm mass in the uncinate pancreatic process, with characteristics of an endocrine neoplasm (arrow).

Figure 4
Figure 4

Pancreatic endocrine tumour ("insulinoma") adjacent to the pancreatic parenchyma (Hematoxylin-Eosin × 100).

Figure 5
Figure 5

Pancreatic endocrine tumour, intensely immunostained for insulin (x 100).


The main clinical symptom in insulinoma patients is the inability to suppress insulin secretion in the presence of hypoglycaemia, resulting in neuroglycopenia and adrenergic manifestations like headache, confusion, visual troubles, shivering, irritability and palpitations [5]. However, establishing a diagnosis in patients with insulinoma is difficult and the imaging studies still have low sensitivity and specificity. The sensitivity of abdominal US is 50% whereas in contrast enhanced CT scan is 24%, in MRI scan is 40% and in scintigraphy using octreotide approaches 60%. Endoscopic US is the most accurate non-interventional imaging modality detecting 77% of the pancreatic insulinomas [6, 7]. However, intraoperative US is even more accurate detecting 90% of these lesions, which are usually smaller than 2cm in maximum diameter [8].

In our case, palpation of the lesion in the uncinate process during the first operation thought to be the mass, which had been demonstrated on the preoperative abdominal CT. Unfortunately, we missed the 1.5cm insulinoma and the resected area revealed a 1mm pancreatic adenocarcinoma with severe desmoplastic reaction in the surrounding tissue, which when palpated obviously misled us to believe that it corresponded to the insulinoma. The patient's symptoms pertained and serial CT scans revealed the 2cm insulinoma which was successfully treated with a Whipple's procedure.

Mixed pancreatic tumours, either collision or composite ones, from endocrine and exocrine cells have been reported in the literature [9], as well as the coexistence of insulinoma and gastrointestinal stromal tumours especially in patients with neurofibromatosis type I [10]. However, the concurrence of pancreatic adenocarcinoma and insulinoma has never been reported before.


The coexistence of pancreatic adenocarcinoma and insulinoma is very rare and has never been reported before. Clinical symptoms should be evaluated carefully and since imaging modalities have low sensitivity and specificity in detecting small endocrine neoplasms, sequential imaging studies and intraoperative US can prove very helpful.



Authors’ Affiliations

Department of Surgery, University of Athens, Aretaieion University Hospital, 76 Vas. Sofias Ave., 11528 Athens, Greece
Unit of Endocrinology, University of Athens, Aretaieion University Hospital, 76 Vas. Sofias Ave., 11528 Athens, Greece
Department of Pathology, University of Athens, Aretaieion University Hospital, 76 Vas. Sofias Ave., 11528 Athens, Greece


  1. Service FJ, McMahon MM, O'Brien PC, Ballard DJ: Functioning insulinoma- incidence, recurrence and long-survival of patients: a 60-year study. Mayo Clin Proc. 1991, 66: 711-719.View ArticlePubMedGoogle Scholar
  2. Kuzin NM, Egorov AV, Kondrashin SA, Lotov AN, Kuznetzov NS, Majorova JB: Preoperative and intraoperative topographic diagnosis of insulinomas. World J Surg. 1998, 22: 593-597. 10.1007/s002689900440.View ArticlePubMedGoogle Scholar
  3. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ: Cancer statistics, 2005. CA Cancer J Clin. 2005, 55: 10-30. 10.3322/canjclin.55.1.10.View ArticlePubMedGoogle Scholar
  4. Zervos EE, Rosemurgy AS, Al-Saif O, Durkin AJ: Surgical management of early-stage pancreatic cancer. Cancer Control. 2004, 11: 23-31.PubMedGoogle Scholar
  5. Grant CS: Gastrointestinal endocrine tumours. Insulinoma. Baillieres Clin Gastroenterol. 1996, 10: 645-671. 10.1016/S0950-3528(96)90017-2.View ArticlePubMedGoogle Scholar
  6. Grant CS: Surgical aspects of hyperinsulinemic hypoglycemia. Endocrinol Metab Clin North Am. 1999, 28: 533-554. 10.1016/S0889-8529(05)70087-6.View ArticlePubMedGoogle Scholar
  7. Gibril F, Reynolds JC, Doppman JL, Chen CC, Venzon DJ, Termanini B, Weber HC, Stewart CA, Jensen RT: Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med. 1996, 125: 26-34.View ArticlePubMedGoogle Scholar
  8. Hashimoto LA, Walsh RM: Preoperative localization of insulinomas is not necessary. J Am Coll Surg. 1999, 189: 368-373. 10.1016/S1072-7515(99)00163-5.View ArticlePubMedGoogle Scholar
  9. Capella C, La Rosa S, Uccella S, Billo P, Cornaggia M: Mixed endocrine-exocrine tumors of the gastrointestinal tract. Semin Diagn Pathol. 2000, 17: 91-103.PubMedGoogle Scholar
  10. Teramoto S, Ota T, Maniwa A, Matsui T, Itaya N, Aoyagi K, Kusanagi H, Narita M: Two von Recklinghausen's disease cases with pheochromocytomas and gastrointestinal stromal tumors (GIST) in combination. Int J Urol. 2007, 14: 73-74. 10.1111/j.1442-2042.2006.01601.x.View ArticlePubMedGoogle Scholar


© Athanasopoulos et al; licensee BioMed Central Ltd. 2011

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.